Results 161 to 170 of about 153,260 (279)

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Targeting opportunities presented by the pyrimidine biosynthesis pathway in Mycobacterium tuberculosis: a brief review. [PDF]

Biochem Soc Trans
Alberti M, Miggiano R.
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Multichannel Coupling in the Electronic Excitation of Pyrimidine Induced by Low-Energy Electron Impact. [PDF]

J Phys Chem A
Silva MO, Bettega MHF, da Costa RF.
europepmc   +1 more source

Adrenal pheochromocytoma impacts three main pathways: cysteine-methionine, pyrimidine, and tyrosine metabolism

Chong Lai, Qingling Yang, Yunuo Zhang, Renjie Gong, Majie Wang, Jiankang Li, Maode Lai, Qingrong Sun   +7 more
openalex   +2 more sources

FB23‐2 and Cisplatin Synergize to Inhibit Head and Neck Squamous Cell Carcinoma by Targeting the XPF/ERCC1 Complex

Cancer Science, EarlyView.
FB23‐2 potentiates cisplatin's antitumor efficacy in head and neck squamous cell carcinoma by disrupting XPF/ERCC1 complex assembly and nuclear translocation, thereby suppressing DNA damage repair machinery and amplifying platinum‐induced tumor cell death.
Yaoqi Jiang, Hongshi Cai, Yue Zhu, Jianfeng Liang, Hongyu Li, Fan Song, Ziyi Wang, Jinsong Hou   +7 more
wiley   +1 more source

Design, synthesis and evaluation of new pyrazino[1',2':1,5]pyrrolo[2,3-<i>d</i>]pyrimidines as tacrine-like acetylcholinesterase inhibitors. [PDF]

RSC Adv
Muzychka LV, Muzychka OV, Kobzar OL, Vovk AI, Smolii OB.   +4 more
europepmc   +1 more source

Glycolysis and pyrimidine biosynthesis are required for replication of adherent–invasive Escherichia coli in macrophages

, 2016
A. Thompson, Ian O’Neill, Emma Jane Smith, John Catchpole, Ailís Fagan, Karl Burgess, Ruaidhrı́ J. Carmody, David J. Clarke   +7 more
openalex   +2 more sources

Integrating network pharmacology, microbiomics, and metabolomics to uncover the therapeutic effect of Liubao tea on osteoarthritis. [PDF]

Front Immunol
Le G, Wen R, Huang Z, Fang H, Zheng J, Wang Y, Luo H.   +6 more
europepmc   +1 more source

Studies on Pyrimidine Derivatives. VII

, 1960
Kenzo Sirakawa
openalex   +2 more sources